Abstract
Complex developmental processes such as hematopoiesis require a series of precise and coordinated changes in cellular identity to ensure blood homeostasis. Epigenetic mechanisms help drive changes in gene expression that accompany the transition from hematopoietic stem cells to terminally differentiated blood cells. Genome-wide profiling technologies now provide valuable glimpses of epigenetic changes that occur during normal hematopoiesis, and genetic mouse models developed to investigate the in vivo functions of chromatin modifying enzymes clearly demonstrate significant roles for these enzymes during embryonic and adult hematopoiesis. Here we will review the basic science aspects of chromatin modifications and the enzymes that add, remove, and interpret these epigenetic marks. This overview will provide a framework for understanding the roles that these molecules during normal hematopoiesis. Moreover, a number of chromatin modifying enzymes are involved in hematological malignancies, underscoring the importance of establishing and maintaining appropriate chromatin modification patterns to normal hematology.
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Chromatin structure and epigenetic mechanisms
Hematopoiesis is an orderly process that involves the coordination of stem cell self-renewal, controlled expansion of progenitor cells, and timely differentiation. Developmental programs, such as hematopoiesis, are orchestrated by changes in gene expression patterns. These patterns are directed by transcription factors, and the actions of these factors are strongly influenced by the chromatin structures of their target genes.
The basic repeat unit of chromatin is the nucleosome, which contains two copies of each core histone protein, H3, H4, H2A, and H2B and 146 base pairs of DNA spooled around the histone octamer. Histone H3 and histone H4 form a heterotetramer at the heart of the nucleosome, and two heterodimers of histones H2A and H2B associate with the tetramer to complete the octamer. Linker histones, typified by H1, bind to DNA entering into and exiting from the nucleosome, thereby providing further structural stability.
Chromatin that is in an open configuration, accessible to transcription factors and RNA polymerase, is often referred to as euchromatin, reflecting a less condensed appearance in microscopic images of nuclear sections.
Heterochromatin, in contrast, refers to more densely packed structures that are generally transcriptionally silent. Regions of the genome that include telomeres and centromeres are highly heterochromatic. Chromatin organization in other regions of the genome is more dynamic, reflecting changes in transcriptional competence and activity. Such plasticity is essential for regulation of various For personal use only. on October 22, 2017 . by guest www.bloodjournal.org From cellular processes such as cell division, gene transcription, DNA repair, replication, and recombination.
The term epigenetics is defined as inherited variation that occurs without changes in the DNA sequence 1 . Epigenetic mechanisms permit a level of plasticity for the genetic information encoded by the DNA, which allows for the establishment of cell-specific expression programs. Modifications added to or removed from the chromatin template that carry epigenetic information include DNA methylation and histone post-translational modifications. Non-coding RNA molecules are also emerging as important regulators of gene expression during hematopoiesis 2, 3 . However, this review will highlight examples of the essential roles that chromatin modifying enzymes play during hematopoietic cell development by regulating the dynamic nature of DNA and specific histone modifications, namely methylation and acetylation.
DNA modifications
Methylation of a cytosine residue in the context of a CpG dinucleotide represents a stable regulatory mark in the mammalian genome. Cytosine methylation (5mC) is generally associated with heterochromatin formation and transcriptional repression. Conversely, stretches of unmethylated CpG dinucleotides, termed CpG islands, are often found in the promoters of actively transcribed genes and support a euchromatic environment. Additional functional groups were recently discovered to modify the 5-position of cytosine residues, namely hydroxymethyl (5hmC), formyl (5fC), and carboxyl (5caC), and the For personal use only. on October 22, 2017 . by guest www.bloodjournal.org From biological functions of these modifications throughout the genome are now being discovered 4 .
Covalent post-translational modification of histone proteins
Post-translational modifications (PTMs) occurring on histone proteins regulate chromatin structure in a temporal and spatial manner. Histone modifications serve both as a signaling mechanism and as binding platforms to recruit other proteins. Covalent PTMs added to the core histone proteins include acetylation, methylation, phosphorylation, ubiquitination, sumoylation, ADP ribosylation, and biotinylation. The 'writers' and 'erasers' that govern the addition or removal of these PTMs often demonstrate site specificity, however multiple enzymes are capable of modifying the same residue within a histone substrate.
Different patterns of histone PTMs have been proposed to act as a 'code' in that specific patterns confer specific biological responses 5, 6 . The 'histone code' hypothesis requires a way for effector molecules to interpret the information given by histone PTMs to mediate cellular process outside of chromatin. Protein domains that recognize individual or combinatorial histone modifications have been termed 'reading' or presenting domains 7 . As more histone PTM reading domains are discovered, linking binding patterns to associated biological responses is becoming more complex. Accumulating evidence links deregulation of histone PTM interpretation with oncogenic transformation, highlighting the importance of histone reader proteins Figure 1A) . Lysine residues can accommodate up to three methyl groups (mono-, di-, or tri-), while arginine residues may be mono-or dimethylated, yielding monomethyl arginine (MMA), asymmetric dimethyl arginine (ADMA), or symmetric dimethyl arginine (SDMA).
The degree of methylation at a particular lysine or arginine residue is just as important in influencing biological outcome as the target site (Figure 1 ).
Chromatin modifications mark genomic regions
Many chromatin modifications are associated with either transcriptional activation or repression (Table 1) , however, there are certainly exceptions to these assignments. The degree of a modification and where the modifications are located within genic regions affect the transcriptional outcome. Often, multiple enzymes modify a particular amino acid residue within a histone protein.
The chromatin modifying enzymes discussed in this review are listed in Table 1 along with their identified substrates, and For personal use only. on October 22, 2017. by guest www.bloodjournal.org From Genome-wide mapping of H3K4me3 and H3K27me3 in hematopoietic stem and progenitor cells revealed the presence of bivalent domains marking genes involved in lineage specification 21, 22 . Furthermore, the level of H3K4me3 in the progenitor cells significantly correlated with the expression of the marked genes in differentiated cell types 22 . These results suggest that the plasticity of the chromatin landscape is crucial for the transition between multipotent and differentiated states.
Writers, erasers, and readers of chromatin modifications
Recent literature is replete with examples demonstrating roles for chromatin modifying enzymes during hematopoiesis. Moreover, genes encoding these enzymes are frequently disrupted in hematological malignancies ( Table 2) 
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. While genome-wide profiling methods provide snapshots of the chromatin landscape during hematopoiesis, genetic mouse models have afforded insights into the roles of chromatin modifying enzymes during this process.
DNA methyltransferases (DNMTs) catalyze 5mC
In mammals, the principal enzymes that catalyze cytosine methylation are members of the DNMT1 and DNMT3 families. DNMT1 primarily serves as a maintenance enzyme by copying cytosine methylation patterns from a hemimethylated substrate following DNA replication 24 . The DNMT3 family includes two active enzymes, DNMT3a and DNMT3b, each of which is further represented by several isoforms. DNMT3a and 3b are referred to as de novo 26, 27 . Absence of Dnmt1 activity led to decreased self-renewal capacity 26 and a rapid ablation of the HSC pool enzyme is crucial to maintain normal hematopoiesis [30] [31] [32] . DNMT1, 3a, and 3b physically and functionally interact with one another, thereby making it more difficult to ascribe the terms "maintenance" or "de novo"
For personal use only. on October 22, 2017. by guest www.bloodjournal.org From to any particular enzyme 25 . Defining genomic targets of these enzymes will aid in assigning distinct functions. Taken together, these studies indicate that while the mechanisms are not yet clearly defined, appropriate expression and activity of DNA methyltransferases is essential during development and for adult blood homeostasis.
TET (Ten-eleven translocation) enzymes catalyze 5hmC
The TET family of enzymes, composed of TET1, TET2, and TET3, catalyze the oxidation of 5mC to 5hmC, which is an intermediate product of DNA demethylation mechanisms, and is proposed to have functional roles in stem cell biology 4 . The TET enzymes have distinct expression patterns, with TET1 expressed in the fetal liver, TET2 in bone marrow, and both TET2 and TET3 in peripheral blood 33 , suggesting unique functions for these enzymes during developmental and adult hematopoiesis. Recently, mutations within TET2 were identified as a prevalent occurrence in myeloid malignancies, prompting intense investigations to define the molecular function of TET2 during hematopoiesis 34, 35 .
Mice lacking Tet2 are viable, but develop hematopoietic malignancies within 2-6 months [36] [37] [38] [39] . HSCs obtained from Tet2-deficient mice exhibit enhanced self-renewal capacity and achieve a greater contribution to peripheral blood production in transplanted recipients, compared to wild-type HSCs [36] [37] [38] [39] .
The overall differentiation potential of HSCs was impeded in the absence of Tet2, with a bias toward expansion of monocyte and macrophage lineages [36] [37] [38] .
Disease progression resembling human CMML was the most common phenotype observed in the Tet2-null mouse models 36, 38, 39 . In addition, myeloid disorders similar to MPD-like myeloid leukemia, myeloid leukemia with maturation, and MDS were reported to cause lethality in approximately one-third of Tet2-null mice 36 .
Mutations that disrupt TET2 enzymatic activity and correlate with decreased global 5hmC levels are observed in patients with myeloid malignancies 40 . TET2 mutations have also been detected in lymphoid malignancies, suggesting that mutations occur in early hematopoietic progenitors with myeloid and lymphoid potential 39 . Moreover, TET2 mutations identified in patients are often monoallelic, indicating that haploinsufficiency contributes to transformation 34, 38, 39 . Heterozygous gain-of-function mutations in the isocitrate dehydrogenase 1 and 2 (IDH1/2) enzymes, which are prevalent in AML, cause inhibition of TET2 catalytic activity and result in increased global 5mC levels, similar to the effect induced by loss of TET2 function 41 .
DNA demethylation mechanisms
The passive loss of cytosine methylation following DNA replication is a widely accepted mechanism for the removal CpG methylation. The direct removal of a methyl group from DNA is thermodynamically unfavorable 42 .
However, recently several pathways have been proposed to mediate indirect, yet active removal of CpG methylation.
TET enzymes catalyze sequential oxidation reactions that convert 5mC to 5hmC, 5fC, and finally to 5caC, which can be removed by DNA repair mechanisms 43 . An alternative proposed active mechanism is deamination of
by activation-induced cytidine deaminase (AID), yielding a thymidine base that is subject to subsequent DNA mismatch repair and base excision repair mechanisms 42 . While these mechanisms do not directly return the methylated cytosine to an unmodified base, the 5mC functionality is no longer present.
Defining DNA demethylation mechanisms is an active area of investigation that is likely to yield exciting results in the future.
DNA methylation readers
Methyl binding domains (MBD) recognize and bind to 5mC, and are found in a conserved family of proteins that includes MBD1, MBD2, MBD3, MBD4, and 45, 46 .
The SRA domain within UHRF1, a DNMT1 interacting partner, and the MBD domain of MBD3 were recently reported as readers of 5hmC 47, 48 . The UHRF1 SRA domain was previously shown to bind hemimethylated DNA 49 . It will be interesting to learn whether these molecular functions overlap or if they occur as distinct targeting mechanisms.
The specificity and affinity of MBD domains for 5mC have made them valuable reagents in defining global cytosine methylation patterns 50 . The MBD domain MBD2 was recently used to affinity-purify methylated DNA fragments
mouse HSCs, CMPs, and erythroblasts in order to determine changes in 5mC during myeloid differentiation. Using this method, a high level of 5mC was detected in mouse HSCs with a dramatic loss of global methylation occurring during myeloid differentiation 51 , similar to results obtained from a DNA methylation profiling study performed during erythropoiesis using a bisulfitebased method 52 . A similar approach employing the MBD domain of MeCP2 was used to detect DNA methylation changes during later stages of lymphoid differentiation, however no dramatic change in 5mC patterns were noted 53 , suggesting that global changes in DNA methylation accompany early differentiation events during hematopoiesis. Notably, the affinity capture approach can be applied to map the genomic locations of CpG islands using domains that recognize unmethylated CpG sites 54 .
Histone acetyltransferases (HATs) and deacetylases (HDACs)
A number of HAT enzymes have been identified as regulators of chromatin-templated processes, including gene transcription and DNA repair.
Most HATs function within large multimeric complexes that include targeting subunits and additional histone modifying activities. In mice, homozygous deletion of the HAT MOZ leads to reduced numbers of hematopoietic progenitors, although all lineages are represented, indicating that differentiation and lineage commitment are not altered 55, 56 . Acetylation is a reversible reaction and HDAC enzymes carry out deacetylation of histones as well as non-histone substrates. The expression of HDACs 1,2,3 is low in hematopoietic progenitor cells but increases during differentiation. However, overexpression of HDAC1 was shown to inhibit myeloid differentiation 57 . HDACs are notoriously linked with hematological malignancies through their association with leukemogenic fusion proteins, and mediate aberrant transcriptional repression of genes required for hematopoietic differentiation 58 . Small molecule HDAC inhibitors are used for leukemia therapy independently, but are more successful when given in combination with other cytotoxic agents 59 . Defining the genomic targets of HDACs will aid in developing inhibitors that specifically target those enzymes modifying genes involved in oncogenesis.
Acetylation readers
Many of the enzymes responsible for 'writing' and 'erasing' histone modifications contain domains that 'read' modifications. Bromodomains are wellcharacterized modules that bind acetylated lysine residues Consistently, EZH2 activity was previously found to be essential during the early stages of B cell development, but dispensable for the maturation and activation of pro-B cells 75 . Notably, mutations abrogating the catalytic function of EZH2 were recently identified in acute and chronic myeloid malignancies [76] [77] [78] [79] , while gain-of function mutations were identified in B cell lymphomas 80, 81, 23 .
Inhibiting the methyltransferase activity of EZH2 in lymphoma patients carrying activating mutations might be a promising therapeutic endeavor. Treatment with an EZH2-specific small molecule inhibitor resulted in decreased lymphoid cell proliferation in vitro and in mouse xenograft models 82 .
A number of point mutations in the polycomb-associated gene addition of sex combs-like 1 (ASXL1) have been identified in patients with MDS or AML, and correlate with a poor prognosis [83] [84] [85] [86] . ASXL1 mutations promote transformation by decreasing the recruitment of PRC2 to leukemogenic target genes resulting in For personal use only. on October 22, 2017. by guest www.bloodjournal.org From loss of histone H3K27 methylation and transcriptional repression of those genes 87 . Given that gain or loss of function mutations affecting various components of the PRC2 complex suggests that altering PRC2 activity and/or H3K27 methylation levels in either direction is detrimental to normal hematopoiesis.
The disruptor of telomeric silencing 1-like (DOT1L) enzyme methylates the globular domain of histone H3 at K79, which correlates with active transcription 88 . Mice deficient for Dot1L exhibit severe anemia and die between E10.5-13.5 89 . Erythroid development was specifically inhibited in Dot1L-null mice, and altered H3K79 methylation status and expression of the erythroid regulatory genes, Gata2 and Pu1, was observed 89 . Conditional targeting strategies revealed a role for Dot1L in maintaining adult hematopoiesis as well 90, 91 .
Notably, aberrant recruitment of DOT1L by several MLL fusion proteins to genes involved in cellular transformation is a common mechanism underlying MLLmediated leukemogenesis 13, 92 . Moreover, DOT1L is a promising therapeutic target in mixed myeloid leukemias in which MLL and/or AF10 oncogenic fusion proteins are expressed 93, 94 . Histone lysine methylation is dynamic and is regulated by lysine (K) demethylase (KDM) enzymes. Two classes of KDMs acting on histones have been identified: amine oxidases and jumonji C (JmjC) domain-containing enzymes. LSD1 was the first histone KDM identified and exhibits dual substrate specificity for histone H3K4 and K9 95, 96 . LSD1 interacts with transcriptional repressors and demethylates histone H3K4me1,2 yielding an unmodified lysine residue. LSD1 and HDACs1 and 2 interact with the TAL1 transcription factor in 
